Skip to content
Close
SEARCH
Contact us
Contact us

We areCambridge Healthcare Innovations

We are empowering a new era for respiratory medicine through the development of novel DPI platforms.

Same company but a new look

To learn more about the inspiration behind the new identity, click here.
Old CHI identity
THEN
New CHI identity
NOW

Patient benefits

Our primary driver is to improve patient outcomes, whether that is saving lives, improving health, or reducing pain and discomfort. But how?

  • By making respiratory drug delivery suitable for a wide range of conditions
  • By ensuring the effective delivery of API to the target region of the patient’s lung
  • By delivering consistent and reliable performance
  • By making inhalers easy to use
  • By minimising throat and mouth deposition (and therefore side effects or discomfort)
  • By making inhalers suitable to use across a range of patient cohorts.

Pharmaco benefits

The drug development process is complex and costly. Our DPI platforms make it faster, easier and cheaper for pharmaceutical companies to bring respirable drugs to market by offering:

  • Platform technology that opens up respiratory drug delivery to many more therapy areas and drugs
  • Our DPI engines can be used during drug discovery and scaled up through clinical trials to market approval, ensuring a consistent platform throughout and reducing the statistical burden
  • Engines that can be fine-tuned to specific formulations
  • Quattrii and Aeolus can be used for API-only or carrier-based formulations
  • All of our DPI engines are designed to be suitable for a wide range of patient profiles.